Saturday, October 3, 2026

GBP/EUR Over 2% Down In The Last 21 Sessions

ViaNews Editorial Team

November 14, 2023

GBP/EUR Over 2% Down In The Last 21 Sessions

(VIANEWS) - GBP/EUR (GBPEUR) has been up by 2.07% for the last 21 sessions. At 05:08 EST on Tuesday, 14 November, GBP/EUR (GBPEUR) is $1.15.

GBP/EUR's yearly highs and lows, it's 3.017% up from its 52-week low and 2.54% down from its 52-week high.

Volatility

GBP/EUR's last week, last month's, and last quarter's current intraday variation average was a negative 0.17%, a negative 0.04%, and a positive 0.19%, respectively.

GBP/EUR's highest amplitude of average volatility was 0.17% (last week), 0.18% (last month), and 0.19% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, GBP/EUR's Forex is considered to be overbought (>=80).

News about

  • Usd/jpy recovers from sudden plunge, on Japanese authorities intervention threats. According to FXStreet on Monday, 13 November, "Following a probable intervention, the USD/JPY is forming a 'spinning top,' and a 'double top' chart pattern could be emerging, though a break of the latest cycle low, seen at 149.18, is crucial to pave the way for a pullback. ", "The USD/JPY paired some of its earlier losses after plunging 67 pips in the last hour to a daily low of 151.20 amid the lack of news and reiterating comments of Japanese authorities that FX moves are undesirable and reflect fundamentals. "
  • Usd/jpy technical analysis: cautious waiting for Japanese intervention - 13 November 2023. According to DailyForex on Monday, 13 November, "In the near term, and according to the performance on the hourly chart, it appears that the USD/JPY currency pair is trading within an ascending channel formation. ", "In the long term, and according to the performance on the daily chart, it also appears that the USD/JPY is trading within an upward channel. "
  • Usd/jpy: position for a trading range 145-150 from now until Q1 2024 – TDS. According to FXStreet on Monday, 13 November, "Likely, MoF officials are buying time for the BoJ and may choose to ease off the pressure on USD/JPY through FX interventions as a weak JPY has become a political issue for the government amid rising cost-of-living pressures."
  • Usd/jpy price analysis: moves on the upward trajectory toward 152.00 level. According to FXStreet on Monday, 13 November, "On the flip side, the USD/JPY pair could meet the support at the 21-day Exponential Moving Average (EMA) at 150.35, followed by the 150.00 psychological level. ", "(This story was corrected on November 13 at 10:30 GMT to say, in the second paragraph,that the USD/JPY next resistance level is at 152.50, not support level.)"
  • Forex today: usd/jpy reaches new 1-year high price - 13 November 2023. According to DailyForex on Monday, 13 November, "Forex Brokers We Recommend in Your Region See full brokers list 1 Read full review Get Started BrokerGeoLists.push({type:'ReviewsNonPartner',id:'horizontal-top-5',size:5,fullReviewText:`Read full review`,getStartedText:`Get Started`,readReviewText:`Review`});The US Dollar is strong, as it was at the end of last week, and this has boosted the USD/JPY currency pair to a new 1-year high price below ¥152. "

More news about GBP/EUR (GBPEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com